AbbVie Inc (NYSE: ABBV), a research-driven biopharmaceutical company, announced on Friday the decision by its board of directors to increased the company's quarterly cash dividend by 11% from USD0.64 per share to USD0.71 per share.
This increased cash dividend is payable on 15 February 2018 to shareholders of record at the close of business on 12 January 2018.
Since the company's inception in 2013, AbbVie said it has increased its dividend by over 77%.
AbbVie works in the four primary therapeutic areas of immunology, oncology, virology and neuroscience.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government